康艾注射液对ⅡB和Ⅲ期结肠癌患者的免疫调节作用和远期临床疗效的影响  

Effects of Kang'ai injection on immunomodulation and long-term clinical outcome in patients with stage ⅡB or Ⅲ colon cancer

作　　者：许斌[1] 阮鹏[1] 徐唐鹏[1] 王世东[1] Xu Bin;Ruan Peng;Xu Tangpeng;Wang Shidong(Department of Oncology,People＇s Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院肿瘤一科,湖北武汉430060

出　　处：《实用肿瘤杂志》2018年第5期429-432,共4页Journal of Practical Oncology

摘　　要：目的观察康艾注射液对ⅡB和Ⅲ期结肠癌患者的免疫调节作用及远期临床疗效的影响。方法选择ⅡB和Ⅲ期结肠癌患者136例,采用信封法分为对照组和治疗组。对照组:奥沙利铂(120 mg/m2)+亚叶酸钙(200 mg/m2)+氟尿嘧啶(2 400 mg/m2),14 d为1个周期,治疗12个周期。观察组在对照组的基础上加用康艾注射液40 m L静脉滴注,每天1次,10 d为1个周期,共治疗4个周期。每组68例。流式细胞仪检测患者治疗前、后外周血CD4+和CD8+T淋巴细胞的比例变化。结果治疗前两组CD4+、CD8+T淋巴细胞的比例和CD4+/CD8+比值比较,差异均无统计学意义(均P>0.05)。治疗后观察组CD4+T淋巴细胞比例和CD4+/CD8+比值均高于对照组(均P<0.05)。治疗后观察组CD8+T淋巴细胞比例低于对照组(P<0.05)。观察组近期临床治疗有效率高于对照组(83.8%vs 69.1%,P<0.05),控制率高于对照组(91.2%vs 82.4%,P<0.05)。观察组1年后复发转移率低于对照组(17.6%vs 30.9%,P<0.05),1年生存率高于对照组(89.7%vs 77.9%,P<0.05)。结论康艾注射液辅助治疗ⅡB和Ⅲ期结肠癌,可以提高CD4+T淋巴细胞比例和CD4+/CD8+比值,增强免疫功能,提高患者的远期临床疗效。Objective To examine the effects of Kang＇ai injection on the immunomodulatory activities and the longterm clinical outcome in patients with stage ⅡB or Ⅲ colon cancer. Methods A total of 136 patients with stage ⅡB or Ⅲcolon cancer were randomly assigned into the control group and the study group with 68 cases in each group by sealed envelope method. All patients were treated with oxaliplatin（ 120 mg/m^2）,calcium folate（ 200 mg/m^2）,and fluorouracil（ 2 400 mg/m^2） for 12 cycles with 14 d as one cycle,while patients in the study group additionally received 40 mL intravenous drip of Kang＇ai injection once a day for 4 cycles with 10 d as one cycle. Flow cytometry was used to examine the changes of the percentages of CD4＋and CD8＋lymphocytes in the peripheral blood before and after the treatment. Results Before the treatment,no significant difference was observed in the percentage of CD4＋and CD8＋lymphocytes and the ratio of CD4＋/CD8＋between the two groups（ all P 0. 05）. After the treatment,the percentage of CD4＋T lymphocytes and ratio of CD4＋/CD8＋were increased and the percentage of CD8＋cells was decreased in the study group compared with the control group（ all P 0. 05）. Moreover,the short-term clinical effect was higher in the study group than that in the control group（ 83. 8% vs 69. 1%,P 0. 05）,and the tumor control rate was also higher in the study group（ 91. 2% vs 82. 4%,P 0. 05）. Finally,the study group had lower 1-year recurrence rate（ 17. 6% vs 30. 9%,P 0. 05） and higher 1-year survival rate（ 89. 7% vs 77. 9%,P 0. 05）. Conclusion Kang＇ai injection is effective as an adjuvant therapy for stage ⅡB and Ⅲ colon cancer,which boosters the immunity function and improves the long-term clinical outcome for patients.

关 键 词：结肠肿瘤/中西医结合疗法 有机铂化合物/治疗应用 黄芪△/治疗应用 苦参/治疗应用 人参△/治疗应用 抗肿瘤药(中药)/投药和剂量 抗肿瘤药/投药和剂量 T淋巴细胞 肿瘤复发 局部 肿瘤转移 存活率 

分 类 号：R735.35[医药卫生—肿瘤] R730.5[医药卫生—临床医学]